BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 11511021)

  • 1. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.
    McCloskey EV; Guest JF; Kanis JA
    Drugs; 2001; 61(9):1253-74. PubMed ID: 11511021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
    J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost of bisphosphonate therapy in tumor bone disease.
    Body JJ
    Cancer; 2003 Feb; 97(3 Suppl):859-65. PubMed ID: 12548587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of bisphosphonates in breast and prostate cancers.
    Brown JE; Neville-Webbe H; Coleman RE
    Endocr Relat Cancer; 2004 Jun; 11(2):207-24. PubMed ID: 15163299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonates and bone metastases].
    Lortholary A; Jadaud E; Berthaud P
    Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of bisphosphonates in cancer.
    Coleman RE; Purohit OP; Vinholes JJ
    Acta Oncol; 1996; 35 Suppl 5():23-9. PubMed ID: 9142961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of bisphosphonates in patients with breast cancer.
    Van Poznak CH
    Cancer Control; 2002; 9(6):480-9. PubMed ID: 12514566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate therapy in multiple myeloma: past, present, future.
    Jantunen E
    Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should bisphosphonates be the treatment of choice for metastatic bone disease?
    Coleman RE
    Semin Oncol; 2001 Aug; 28(4 Suppl 11):35-41. PubMed ID: 11544574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of bisphosphonates in breast cancer management: review article.
    Pickering LM; Mansi JL
    Curr Med Res Opin; 2002; 18(5):284-95. PubMed ID: 12240791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy.
    Kohno N; Kokufu I
    Breast Cancer; 2003; 10(1):33-7. PubMed ID: 12525761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates in the treatment of metastatic breast cancer.
    Body JJ
    J Mammary Gland Biol Neoplasia; 2001 Oct; 6(4):477-85. PubMed ID: 12013536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.